Community Trust & Investment 13F: Exits Zoetis (ZTS) Stake

Community Trust & Investment completely exited its stake in Zoetis Inc. (NYSE: ZTS), selling off all 30,914 shares it previously held. The complete sale was revealed in a Form 13F filing with the SEC on October 15, 2026. Because 13F filings look backward at the previous quarter, this report captures the fund's holdings as of that date and may not reflect its current portfolio.

What Changed in Community Trust & Investment's Zoetis Position

Community Trust & Investment sold its entire remaining stake of 30,914 shares in Zoetis. The complete liquidation closed out the fund's entire investment in the animal health company. Institutional reports like this one show portfolio adjustments made weeks earlier.

Other Institutional Activity in Zoetis

Other large institutional investors adjusted their own positions in Zoetis during the same period. Blackrock Inc. grew its holdings by 3,846,587 shares, ending with 39,430,181 shares worth about $3,129,967,659 after a 10.8% increase. Vanguard Capital Management LLC trimmed its stake by 44,323 shares, ending with 26,027,984 shares worth about $2,066,101,298 following a 0.2% decrease. Vanguard Portfolio Management LLC reduced its holdings by 107,857 shares, leaving it with 23,860,445 shares valued at approximately $1,894,042,058 after a 0.4% cut. State Street Corporation grew its position by 343,963 shares to finish with 19,667,723 shares worth about $1,561,223,797, a 1.8% boost. State Farm Mutual Automobile Insurance Co kept its holdings unchanged at 15,892,903 shares valued at roughly $1,261,578,596.

Zoetis Inc. Stock Up 4.9%

Zoetis shares recently traded around $78.96. The stock's 52-week range sits between a low of $68.77 and a high of $148.30. Its 50-day moving average is $73.86, while the 200-day moving average stands at $96.34. The company carries a market capitalization of roughly $32.40 billion.

Recent Earnings

For its trailing twelve months, Zoetis reported $9.53 billion in revenue and earnings of $6.16 per share. The company posted a net profit margin of 27.7% and a return on equity of 64.9%. The next quarterly earnings report is scheduled for November 5, 2026.

Dividend

Zoetis pays an annual dividend with a current dividend yield of 2.7% and a payout ratio of 33.9%.

Insider Buying and Selling at Zoetis Inc.

Company insiders made several purchases earlier in the year. Director Michael B. Mccallister bought 3,000 shares on May 11, 2026, at an average price of $77.76 for a total value of $233,273. Director Paul M. Bisaro picked up 2,000 shares on May 13, 2026, at $75.88 per share, totaling $151,750. Director Amelio Frank A. D. bought 6,650 shares on May 13, 2026, at $75.39 per share, amounting to $501,344. Mark Stetter purchased 318 shares on June 18, 2026, at $78.71 per share for a total of $25,029.78.

Analysts Set New Price Targets

Wall Street analysts have recently updated their views on the stock. On August 10, 2026, Piper Sandler maintained its Neutral rating while lowering its price target from $90.00 to $80.00. On August 11, 2026, Citigroup kept a Buy rating and cut its price target from $112.00 to $96.00. On August 11, 2026, BNP Paribas maintained an Outperform rating and reduced its target from $146.00 to $110.00. On August 20, 2026, Stifel kept a Hold rating and lowered its target from $85.00 to $80.00. On August 25, 2026, TD Cowen maintained a Buy rating while dropping its target from $104.00 to $94.00. Overall, the stock holds a consensus Buy rating with a mean price target of $93.47.

About Zoetis

Zoetis discovers, develops, and manufactures medicines, vaccines, and diagnostic products for both companion animals like dogs and cats and livestock species including cattle and pigs. The company operates across the global animal health sector from its headquarters in Parsippany, New Jersey.

Bottom Line

Investors tracking institutional ownership shifts should watch for upcoming 13F reports and Zoetis's next earnings release on November 5, 2026. This filing reflects portfolio decisions made during a prior period and does not necessarily represent the fund's current holdings. Keep in mind that 13F filings are backward-looking: they show holdings as of the end of the reporting quarter and may not represent the fund's current position.